• 1
    Shanahan F. Host-flora interactions in inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: S16S24.
  • 2
    Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002; 122: 4454.
  • 3
    Schultsz C, van den Berg FM, ten Kate FW, et al. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology. 1999; 117: 10891097.
  • 4
    Ryan P, Aarons S, Bennett MW, et al. Mycobacterium paratuberculosis detected by nested PCR in intestinal granulomas isolated by LCM in cases of Crohn's disease. Methods Mol Biol. 2002; 193: 205211.
  • 5
    Ryan P, Kelly RG, Lee G, et al. Bacterial DNA within granulomas of patients with Crohn's disease-detection by laser capture microdissection and PCR. Am J Gastroenterol. 2004; 99: 15391543.
    Direct Link:
  • 6
    Rutgeerts P, Geboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet. 1991; 338: 771774.
  • 7
    Elson CO, Sartor RB, Tennyson GS, et al. Experimental models of inflammatory bowel disease. Gastroenterology. 1995; 109: 13441367.
  • 8
    Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004; 126: 414424.
  • 9
    Vermeire S, Rutgeerts P. Antibody responses in Crohn's disease. Gastroenterology. 2004; 126: 601604.
  • 10
    Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411: 603606.
  • 11
    Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411: 599603.
  • 12
    Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal α-defensin expression. Gut. 2004; 53: 16581664.
  • 13
    Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem. 2003; 278: 55095512.
  • 14
    Bonen DK, Ogura Y, Nicolae DL, et al. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology. 2003; 124: 140146.
  • 15
    Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005; 307: 731734.
  • 16
    Cario E, Rosenberg IM, Brandwein SL, et al. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol. 2000; 164: 966972.
  • 17
    Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000; 68: 70107017.
  • 18
    Takeuchi O, Akira S. Toll-like receptors; their physiological role and signal transduction system. Int Immunopharmacol. 2001; 1: 625635.
  • 19
    Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut. 2004; 53: 987992.
  • 20
    Forbes A. Clinical presentation and diagnosis of Crohn's disease. In: SatsangiJ, SutherlandL, eds. Inflammatory Bowel Disease. New York: Churchill Livingstone; 2003: 183189.
  • 21
    Travis S, Jewell DP. Ulcerative colitis: clinical presentation and diagnosis. In: SatsangiJ, SutherlandL, eds. Inflammatory Bowel Disease. New York: Churchill Livingstone; 2003: 169182.
  • 22
    McGovern D, Van Heel D, Negoro K, et al. Innate immunogenetics and inflammatory bowel disease (IBD). Gastroenterology. 2003; 124: A369.
  • 23
    Lorenz E, Mira JP, Cornish KL, et al. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun. 2000; 68: 63986401.
  • 24
    Schmitt C, Humeny A, Becker CM, et al. Polymorphisms of TLR4: rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles. Clin Chem. 2002; 48: 16611667.
  • 25
    O'Connell JR, Weeks DE. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet. 1998; 63: 259266.
  • 26
    Abecasis GR, Cherny SS, Cookson WO, et al. Merlin-rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet. 2002; 30: 97101.
  • 27
    Horvath S, Xu X, Laird NM. The family based association test method: strategies for studying general genotype-phenotype associations. Eur J Hum Genet. 2001; 9: 301306.
  • 28
    Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet. 2001; 357: 19251928.
  • 29
    Ouburg S, Mallant-Hent R, Crusius JB, et al. The toll-like receptor 4 (TLR4) Asp299Gly polymorphism is associated with colonic localisation of Crohn's disease without a major role for the Saccharomyces cerevisiae mannan-LBP-CD14-TLR4 pathway. Gut. 2005; 54: 439440.
  • 30
    Gazouli M, Mantzaris G, Kotsinas A, et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol. 2005; 11: 681685.
  • 31
    Takeda K, Akira S. TLR signaling pathways. Semin Immunol. 2004; 16: 39.
  • 32
    Nakao Y, Funami K, Kikkawa S, et al. Surface-expressed TLR6 participates in the recognition of diacylated lipopeptide and peptidoglycan in human cells. J Immunol. 2005; 174: 15661573.
  • 33
    Vermeire S, Rutgeerts P, Van Steen K, et al. Genome-wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis. Gut. 2004; 53: 980986.